Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.06 EUR -0.98% Market Closed
Market Cap: 71.6m EUR
Have any thoughts about
Vita 34 AG?
Write Note

Vita 34 AG
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vita 34 AG
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Vita 34 AG
XETRA:V3V
Cash from Operating Activities
€10.6m
CAGR 3-Years
39%
CAGR 5-Years
15%
CAGR 10-Years
21%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Cash from Operating Activities
€2B
CAGR 3-Years
-6%
CAGR 5-Years
-3%
CAGR 10-Years
5%
Fresenius SE & Co KGaA
XETRA:FRE
Cash from Operating Activities
€3.1B
CAGR 3-Years
-13%
CAGR 5-Years
-6%
CAGR 10-Years
3%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Cash from Operating Activities
HK$191.9m
CAGR 3-Years
35%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Cash from Operating Activities
€363.1m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Cash from Operating Activities
€2B
CAGR 3-Years
-6%
CAGR 5-Years
-3%
CAGR 10-Years
5%
No Stocks Found

Vita 34 AG
Glance View

Market Cap
70.8m EUR
Industry
Health Care

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

V3V Intrinsic Value
3.52 EUR
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Vita 34 AG's Cash from Operating Activities?
Cash from Operating Activities
10.6m EUR

Based on the financial report for Jun 30, 2024, Vita 34 AG's Cash from Operating Activities amounts to 10.6m EUR.

What is Vita 34 AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
21%

Over the last year, the Cash from Operating Activities growth was 1 653%. The average annual Cash from Operating Activities growth rates for Vita 34 AG have been 39% over the past three years , 15% over the past five years , and 21% over the past ten years .

Back to Top